Northwest Biotherapeutics (NW Bio), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, has received the regulatory approvals necessary to expand manufacturing and distribution of DCVax across Europe. These approvals will enable DCVax-L to be produced in Germany and supplied across borders to the UK for clinical trials evaluating the drug for the treatment of brain cancer. The approval for cross-border supply and distribution provides the flexibility t...